Douglas Earl Martin 4
4 · BIOMIMETIC THERAPEUTICS, INC. · Filed Mar 28, 2012
Insider Transaction Report
Form 4
Douglas Earl Martin
General Counsel
Transactions
- Sale
Common Stock
2012-03-28$2.32/sh−1,100$2,552→ 52,417 total - Sale
Common Stock
2012-03-28$2.34/sh−3,000$7,024→ 38,517 total - Sale
Common Stock
2012-03-28$2.36/sh−5,000$11,800→ 33,517 total - Sale
Common Stock
2012-03-28$2.35/sh−400$940→ 31,817 total - Sale
Common Stock
2012-03-28$2.37/sh−5,000$11,850→ 24,517 total - Sale
Common Stock
2012-03-28$2.33/sh−1,400$3,262→ 47,517 total - Sale
Common Stock
2012-03-28$2.35/sh−1,300$3,055→ 32,217 total - Sale
Common Stock
2012-03-28$2.35/sh−300$705→ 31,517 total - Sale
Common Stock
2012-03-28$2.36/sh−2,000$4,720→ 29,517 total - Sale
Common Stock
2012-03-28$2.38/sh−5,000$11,910→ 19,517 total - Sale
Common Stock
2012-03-28$2.35/sh−8,000$18,822→ 11,056 total - Sale
Common Stock
2012-03-28$2.34/sh−3,300$7,722→ 48,917 total - Sale
Common Stock
2012-03-28$2.37/sh−461$1,093→ 19,056 total - Sale
Common Stock
2012-03-26$2.35/sh−1,100$2,585→ 63,517 total - Sale
Common Stock
2012-03-28$2.35/sh−5,000$11,750→ 53,517 total - Sale
Common Stock
2012-03-27$2.34/sh−5,000$11,700→ 58,517 total - Sale
Common Stock
2012-03-28$2.33/sh−200$466→ 52,217 total - Sale
Common Stock
2012-03-28$2.35/sh−6,000$14,100→ 41,517 total
Footnotes (1)
- [F1]This transaction was made pursuant to the Reporting Person's sale of common stock to allow the Reporting Person to meet Federal income tax obligations resulting from alternative minimum tax liability based on the Reporting Person's exercise of Issuer's stock options in 2010.